Skip to main content
. 2020 May 5;13:3789–3800. doi: 10.2147/OTT.S245346

Figure 7.

Figure 7

miR-145 inhibits PI3K/Akt/mTOR/p70S6K pathway activation in a mouse model of MA (n=5). Construction of a mouse model of MA in liver cancer, and intravenous injection of mmu-miR-145-5pagomir or negative control oligonucleotide. After 2 weeks, mice were sacrificed, and spleen tissue was isolated. PI3K mRNA (A), Akt mRNA (D), mTOR mRNA (G), and p70S6K mRNA (J) were measured by RT-PCR. Western blotting for p-PI3K (B, C), p-Akt (E, F), p-mTOR (H, I), and p-p70S6K (K, L). *P<0.05. ***P<0.01.

Abbreviations: PI3K, phosphatidylinositol-3-kinase; p-PI3K, phosphorylation-phosphatidylinositol-3-kinase; Akt, protein kinase B; p-Akt, phosphorylation-protein kinase B; mTOR, mammalian target of rapamycin; p-mTOR, phosphorylation-mammalian target of rapamycin; p70S6K, p70 ribosomal protein S6 kinase; p-p70S6K, phosphorylation-p70 ribosomal protein S6 kinase; MA, malignant ascites; NC, negative control; RT-PCR, reverse transcription-polymerase chain reaction.